Resistance of melanoma to BRAF inhibition can be elucidated in the context of two different models: the first model is intrinsic resistance, founded upon the Darwinian perspective of evolution, through multiple cycles of natural selection, while the second one is of Lamarckian origin and states that the drug itself prompts cell changes towards a more drug-tolerant state, that can persist across cell generations. The gene discussed is BRAF; the disease is melanoma.